Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis


The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc. and Protopic® (tacrolimus), 0.1% topical ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of moderate to severe atopic dermatitis. The secondary objectives are to compare the adverse event (AE) profiles of the two ointments and to investigate their systemic absorption at steady state.

Full Title of Study: “A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 2010


  • Drug: Tacrolimus 0.1% manufactured by Taro
    • Treatment applied as a thin layer to target area twice daily for 14 days
  • Drug: Protopic – Tacrolimus 0.1%
    • Treatment applied as a thin layer to target area twice daily for 14 days
  • Drug: Tacrolimus Vehicle manufactured by Taro
    • Treatment applied as a thin layer to target area twice daily for 14 days

Arms, Groups and Cohorts

  • Experimental: Tacrolimus 0.1% Taro
    • Tacrolimus 0.1% manufactured by Taro applied for 14 days
  • Active Comparator: Protopic – Tacrolimus 0.1%
    • Protopic, Tacrolimus 0.1% applied for 14 days
  • Placebo Comparator: Vehicle
    • Tacrolimus vehicle applied for 14 days

Clinical Trial Outcome Measures

Primary Measures

  • ISGA score 0 or 1
    • Time Frame: 14 days

Secondary Measures

  • % change in BSA
    • Time Frame: 14 days
  • % change in EASI
    • Time Frame: 14 days
  • % change in ISGA
    • Time Frame: 14 days
  • Safety and adverse event profile
    • Time Frame: 14 days

Participating in This Clinical Trial

Inclusion Criteria

  • Male or non-pregnant, non-lactating female, 18 years of age or older. – Patient has documented evidence that they have been unresponsive to alternative more traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient. – If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives). – Have confirmed diagnosis of atopic dermatitis using the diagnostic features as described by Hanifin and Rajka. – Have an IGSA score of 3 (moderate) or 4 (severe) – Have an affected Body Surface Area (BSA) of at least 20% – Have a minimum Eczema Area and Severity Index (EASI) score of at least 15 Exclusion Criteria:
  • Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2 (mild) OR %BSA affected less than 20% OR EASI Score of less than 15. – Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not indicated for the treatment of clinically infected atopic dermatitis – Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis – Females who are pregnant, lactating or likely to become pregnant during the study. – History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as clindamycin erythromycin – Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer. – Use of any nonsteroidal immunosuppressants – Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2 mg of prednisone/day, within 14 days of the first dosing day. – Use of non-sedating histamines are not allowed for at least 7 days prior to the first dosing day or throughout the study.
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Taro Pharmaceuticals USA
    • Provider of Information About this Clinical Study
      • Sponsor

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.